ECOG-ACRIN NCORP Research Base - TMIST

$18,423,048UG1FY2023CANIH

Ecog-Acrin Medical Research Foundation, Philadelphia PA

Investigators

Lynne I. Wagnercontact Peter J O'Dwyer Mitchell D Schnall

Linked publications, trials & patents

Paper 39573923 Paper 39379409 Paper 39182417 Paper 39028321 Paper 38967884 Paper 38845066 Paper 38828938 Paper 38820500 Paper 38810178 Paper 38768413 Paper 38746356 Paper 38688766 Paper 38640040 Paper 38634292 Paper 38573708 Paper 38536173 Paper 38531002 Paper 38353324 Paper 38255023 Paper 38252911 Paper 38236702 Paper 38194233 Paper 38175992 Paper 37856199 Paper 37830895 Paper 37824821 Paper 37795845 Paper 37433436 Paper 37423348 Paper 37133584 Paper 36963200 Paper 36908314 Paper 36475752 Paper 36468339 Paper 36416677 Paper 36266760 Paper 36229050 Paper 36178937 Paper 36029412 Paper 35930212 Paper 35921034 Paper 35365604 Paper 35226083 Paper 35175284 Paper 35120494 Paper 34995128 Paper 34932888 Paper 34890045 Paper 34846916 Paper 34838280 Paper 34807736 Paper 34614209 Paper 34608052 Paper 34554848 Paper 34342501 Paper 34287690 Paper 34255179 Paper 34246583 Paper 34092112 Paper 34057469 Paper 33932097 Paper 33931863 Paper 33793979 Paper 33783531 Paper 33749062 Paper 33610505 Paper 33594771 Paper 33355237 Paper 33264502 Paper 33163549 Paper 33136296 Paper 33040481 Paper 33022832 Paper 32986828 Paper 32920242 Paper 32866432 Paper 32860331 Paper 32820842 Paper 32699031 Paper 32473681 Paper 32369412 Paper 32271671 Paper 32144626 Paper 32096852 Paper 31852811 Trial NCT06526897 Trial NCT06295367 Trial NCT06112613 Trial NCT06022822 Trial NCT06002828 Trial NCT04597359 Trial NCT04467021 Trial NCT04438382 Trial NCT04239573 Trial NCT04001829 Trial NCT03804255 Trial NCT03516942 Trial NCT03253848 Trial NCT02933489 Trial NCT02352883

Abstract

Project Summary/Abstract The purpose of the TMSIT study is to compare the proporï¿½ons of parï¿½cipants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an âadvancedâ breast cancer at any ï¿½me during a period of 7 years from randomizaï¿½on, including the period of acï¿½ve screening and a period of follow up aï¿½er the last screen. Supplemental funding includes but is not limited to supporï¿½ng site reimbursements to non-NCORP sites, core infrastructure, clinical data collecï¿½on, biospecimen collecï¿½on and analysis, imaging collecï¿½on, staï¿½sï¿½cal analysis, physics quality control program, and central monitoring.

View original record on NIH RePORTER →